[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100382135":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":51,"centralContacts":55,"locations":64,"responsibleParty":82,"collaborators":30,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":30,"eligibilityCriteria":90,"healthyVolunteers":87,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":30,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":108,"overallStatus":66,"whyStopped":30,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology","OTHER",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Change in disease manifestations","EXPERIMENTAL","The data of all the patients will be assessed from the viewpoint of changes in the disease flow (severity and frequency of symptoms, grade of oesophagitis). They will be compared to the changes of the major factors that could influence the disease flow: adherence to anti-secretory agents, presence of concomitant medications and their doses, adherence to diet, change in physical activity. These will be compared to the initial data. Thus, it would be possible to make a multivariate comparison and try to establish the influence (and, possibly, weight) of each of the con-founder on the disease flow.",[13,14,15,16,17,18],"Behavioral: diet adherence","Behavioral: No diet adherence","Behavioral: Change in physical activity","Behavioral: No change in physical activity","Behavioral: Use of antisecretory agents","Behavioral: No use of antisecretory agents",{"label":20,"type":21,"description":22,"interventionNames":23},"No change in disease flow","ACTIVE_COMPARATOR","To this arm patients with no change in the disease manifestations will be assigned, based on the end-point evaluation. The same as in the \"experimental\" groups factors will be analysed to establish the difference.",[13,14,15,16,17,18],[25,31,35,39,43,47],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"BEHAVIORAL","diet adherence","This type of \"intervention\" is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his \"usual\" diet or it contained substantial changes.",[9,20],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"No diet adherence","A-posteriori established \"intervention\" based on the examinations at the end-point",[9,20],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Change in physical activity","The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data",[9,20],{"type":26,"name":40,"description":41,"armGroupLabels":42,"otherNames":30},"No change in physical activity","The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data",[9,20],{"type":26,"name":44,"description":45,"armGroupLabels":46,"otherNames":30},"Use of antisecretory agents","This \"intervention\" will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes.",[9,20],{"type":26,"name":48,"description":49,"armGroupLabels":50,"otherNames":30},"No use of antisecretory agents","This \"intervention\" will be established a-posteriori, based on the examination at the end-point and compared to the baseline data.",[9,20],[52],{"name":53,"affiliation":5,"role":54},"Sergey Morozov, MD, PhD","PRINCIPAL_INVESTIGATOR",[56,60],{"name":53,"role":57,"phone":58,"phoneExt":30,"email":59},"CONTACT","+74996131091","morosoffsv@mail.ru",{"name":61,"role":57,"phone":62,"phoneExt":30,"email":63},"Vasily Kropochev, MD","+74997943572","followkropochev@yandex.ru",[65],{"facility":5,"status":66,"city":67,"state":30,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"RECRUITING","Moscow","115446","Russia","RU",{"type":72,"coordinates":73},"Point",[74,75],37.61781,55.75204,{"lat":75,"lon":74},[78,80],{"name":53,"role":57,"phone":79,"phoneExt":30,"email":59},"+79104681801",{"name":81,"role":57,"phone":62,"phoneExt":30,"email":63},"Vasily Kropochev",{"type":54,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Sergey Morozov","Leading researcher","100382135","real-life-study-of-changes-of-gastroesophageal-reflux-disease-manifestations-due-to-behavioural-and-diet-adherence-100382135",false,"NCT04255693","Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence","Inclusion Criteria:\n\n* willingness to participate (based on the signed informed consent form);\n* presence of gastroesophageal reflux disease, based on the following: a) typical symptoms, like heartburn and\u002For regurgitation (for primary selection, symptoms should be present at least weekly, be actual for at least 3 months prior to the enrolment, and the patient should report the history of symptoms which lasts for at least 6 months); b) previous response to the intake of proton pump inhibitors; c) data of 24-hours oesophageal pH-impedance monitoring with detected pathological gastroesophageal reflux according to the Lyon consensus definitions;\n\nExclusion Criteria:\n\n* pregnant or breast-feeding females;\n* abdominal or chest surgery (except appendectomy or cholecystectomy in case they are not followed by adhesive disease of the abdominal organs);\n* constant use of non-steroidal anti-inflammatory agents (NSAIDs), sporadic use of NSAIDs will be allowed in case the course of treatment was discontinued at least 2 weeks prior to the enrolment, in case that constant use of NSAIDs happen to be necessary after the enrolment, the patients may continue in the study but doses, frequency and duration of treatment should be carefully documented;\n* history or current evidence of cancer of any aetiology and location besides skin cancer in situ successfully treated before the enrolment;\n* severe patient's conditions which may lead to misinterpretation of data, or in case of patient's enrolment may put him at risk of exacerbation of co-morbid conditions, or in cases when on discretion of the investigator patient's condition would not allow him to complete the course of the observation. These conditions include, but not limited to: heart failure (class III-IV by NYHA), uncontrolled hypertension, severe neurological disorders, decompensated liver cirrhosis (Child-Pugh B or C), severe depression or other psychological disorders;\n* the patient may stop his participation in the study at any time by informing the site personal about his\u002Fher decision to withdraw the consent.","ALL","18 Years","80 Years",{"count":95,"type":96},150,"ESTIMATED","INTERVENTIONAL",[99],"NA","This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease",[102,103,104,105,106,107],"Gastroesophageal Reflux Disease","GERD","Gastroesophageal Erosion","Erosive Esophagitis","Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease",[103,109,110,111,112,113,114],"NERD","erosive esophagitis","diet","food","adherence","influence","2025-08-01",{"date":117,"type":118},"2025-08-03","ACTUAL",{"date":120,"type":118},"2020-01-31",{"date":122,"type":96},"2027-12-31",{"name":5,"class":6},1]